Journal
PLANT CELL REPORTS
Volume 35, Issue 7, Pages 1487-1491Publisher
SPRINGER
DOI: 10.1007/s00299-016-1988-9
Keywords
CRISPR/Cas9; Oligonucleotide-directed mutagenesis; Patent landscape; TALE-nucleases; Zinc finger nucleases
Categories
Funding
- Dow AgroSciences
Ask authors/readers for more resources
Genome editing is a revolutionary technology in molecular biology. While scientists are fascinated with the unlimited possibilities provided by directed and controlled changes in DNA in eukaryotes and have eagerly adopted such tools for their own experiments, an understanding of the intellectual property (IP) implications involved in bringing genome editing-derived products to market is often lacking. Due to the ingenuity of genome editing, the time between new product conception and its actual existence can be relatively short; therefore knowledge about IP of the various genome editing methods is relevant. This point must be regarded in a national framework as patents are instituted nationally. Therefore, when designing scientific work that could lead to a product, it is worthwhile to consider the different methods used for genome editing not only for their scientific merits but also for their compatibility with a speedy and reliable launch into the desired market.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available